Capmatinib granted priority review as treatment for NSCLC

07:27 EST 12 Feb 2020 | SmartBrief

Priority review was granted by the FDA to Novartis' new drug application for its investigational drug INC280, or capmatinib,  -More

Original Article: Capmatinib granted priority review as treatment for NSCLC


More From BioPortfolio on "Capmatinib granted priority review as treatment for NSCLC"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...